Novo Nordisk's Victoza Gains First Japanese GLP-1 Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
The type 2 diabetes therapy could soon have competition though, with Lilly's Byetta pending approval and Chugai/Teijin's candidate entering Phase III.